Antibody-mediated epilepsies …

Sarosh R Irani MD

Epilepsy & Seizures

Updated 12.08.2023
Released 11.10.2011
Expires For CME 12.08.2026

Antibody-mediated epilepsies

Author: Sarosh R Irani MD

See Contributor Disclosures

Editor: Jerome Engel Jr MD PhD

Antibody-mediated epilepsies

In This Article

Quick Link

Introduction

Overview

In this article, the author summarizes advances in the field of antibody-mediated epilepsies. This field is best defined by autoantibodies directed against neuronal cell-surface antigens including leucine-rich glioma inactivated 1 (LGI1), contactin-associated protein-like 2 (CASPR2), and the N-methyl, D-aspartate (NMDA), and gamma-aminobutyric acid (GABA) A and B receptors. Importantly, seizures in patients with these autoantibodies are often best treated with immunotherapies. Most strikingly, faciobrachial dystonic seizures have been recognized as a distinctive epilepsy semiology with frequent and brief dystonic episodes, typically involving the face and arm, and are consistently associated with LGI1-antibodies. Findings not only confirm a superior response of faciobrachial dystonic seizures to immunotherapies but also suggest that patients with the ensuring cognitive impairment, recognized in patients who present with faciobrachial dystonic seizures, may be prevented with immunotherapies. In addition, frequent temporal lobe seizures are also recognized in patients with autoantibodies against glutamic acid decarboxylase. Glutamic acid decarboxylase is an intracellular enzyme, and these patients often respond poorly to antiepileptic drugs or immunotherapies. These 2 paradigms imply that a proportion of patients with neuronal autoantibodies have frequent focal seizures with contrasting responses to immunotherapies. Clinical features allow recognition of these patients within unselected general epilepsy populations. This selection is critical for both etiologic and therapeutic implications, and to establish paradigms for recognition with the growing number of autoantibodies described in epileptic disorders.

Key points

	• The antibody-mediated epilepsies often show an abrupt onset of frequent focal seizures with neuropsychiatric features.
	• Faciobrachial dystonic seizures are very frequent brief dystonic events, typically affecting the ipsilateral arm and face, and are associated with LGI1-antibodies. Faciobrachial dystonic seizures often precede LGI1-antibody encephalitis, and early treatment may prevent the progression to “full-blown” encephalitis.
	• Some patients with drug-resistant epilepsies, cryptogenic epilepsies, and new onset refractory status epilepticus have serum autoantibodies directed against neuronal surface proteins such as LGI1, CASPR2, the NMDA receptor, and the intracellular protein GAD.
	• Testing for VGKC-complex antibodies should be halted, as this assay is less sensitive and far less specific for immunotherapy-responsive neurologic syndromes than directed testing for LGI1- and CASPR2-autoantibodies.
	• The spectrum of autoantibody-mediated epilepsies is likely to expand in the near future with the ongoing discovery of new autoantibodies.

Historical note and terminology

In the 1960s, Brierley, Corsellis, and colleagues showed that patients with a subacute onset of amnesia, disorientation, and seizures had histological evidence of limbic system inflammation, predominantly affecting the hippocampi (07; 10). They termed this syndrome “limbic encephalitis.” However, the relevance of observed concurrent systemic malignancy was not fully appreciated at that time. Since this observation, a number of patients with limbic encephalitis and systemic tumors of lung, testicular, breast, and gynecological origin have been reported. The term “paraneoplastic neurologic syndrome” has been used to describe cancer-related conditions that are pathologically remote to the cancer (26), and 1 such paraneoplastic condition is often limbic encephalitis. However, these syndromes appeared to be associated with antibodies directed against intracellular antigens such as Hu, Ma2, and CV2/CRMP5, which are unlikely to be pathogenic, and they showed a low incidence.

These early observations have been significantly extended in recent years with the discovery of a flurry of new autoantibodies. These discoveries have made it clear that limbic encephalitis is more commonly found in association with autoantibodies directed against the extracellular domains of neuronal proteins. These forms of limbic encephalitis can frequently be treated with immunotherapies, and are far less frequently associated with systemic tumors. In addition, some epilepsy patients without evident amnesia or disorientation have been reported to harbor these autoantibodies, supporting the hypothesis of autoimmune forms of epilepsy (53). Indeed, several antigenic targets have now been described as forms of likely causative autoantibodies and have been shown to induce molecular effects consistent with epileptogenesis (73; 61; 63).

Clinical manifestations

Presentation and course

Antibody-associated epilepsy in the setting of encephalitis. Over 2000 patients with antibody-associated encephalitides have been described in the last decade. Most of these patients have seizures as a prominent feature of their illness, sometimes in isolation (02). These conditions have now reached mainstream neurology and are considered frequently by clinicians seeing patients with an acute or subacute onset of amnesia, psychiatric features, disorientation, and/or seizures. Typically, symptoms manifest over days to weeks. Although there are significant clinical differences between patients with the 2 most common antibodies (LGI1 and NMDAR; see Table 1). Overall, in these patients, the seizures often respond relatively poorly to antiepileptic drugs (AEDs) but well to immunotherapies (12; 37; 31; 36; 65; 27; 02). In particular, early immunotherapies appear to offer most substantial benefits (30; 36; 13; 63). One major aim of the immunotherapies is thought to be reduction of antibody levels and accompanying aspects of the underlying inflammatory process. The reduction in antibody levels in particular often correlates modestly well with decreased seizure frequencies in an individual patient, suggesting antibody pathogenicity. With the marked exception of ovarian teratomas in young females with NMDAR-antibodies and some cases of Morvan syndrome with thymomas, it is becoming recognized that the majority of these cases do not have an underlying tumour (30; 35; Vincent et al 2011; 22; 63).

Leucine-rich glioma-inactivated 1 (LGI1) are typically found in patients with limbic encephalitis and faciobrachial dystonic seizures (see Table 1). Males are affected more commonly than females, and the median age of onset is around 63 years with a range from around 20 to 95 years of age. Remarkably few children are described in the literature. They were formally described as a subunit of the VGKC-complex, but the VGKC-complex radioimmunoassay lacks sensitivity and specificity compared to direct testing for LGI1- and CASPR2-antibodies; therefore, it is no longer a useful test and also frequently leads to unnecessary administration of immunotherapies (29; 69; 05).

CASPR2-antibody encephalitis is also frequently associated with seizures (29; 70), and a pure-epilepsy syndrome has also been described in patients with CASPR2-antibodies (67). CASPR2-antibodies are discussed further below in the context of Morvan syndrome.

In addition, other less frequent antibodies directed against the GABAA-, GABAB-, and AMPA-receptors have been detected in a limited number of patients with limbic encephalitis, many of whom have prominent and antiepileptic drug-refractory seizures, and a substantial number of these patients have an underlying tumor (54; 14; 55).

Antibodies against the intracellular protein glutamic acid decarboxylase (GAD) have also been found in a few patients with limbic encephalitis who present with temporal lobe seizures. In 1 study, the frequency of this syndrome was similar to LGI1/CASPR2-antibody limbic encephalitis (47). GAD-antibody encephalitis is usually a nonparaneoplastic condition that often affects young females. The antibodies have a lower likelihood of being pathogenic as they target an intracellular antigen (28), and the levels of the antibody correlate poorly with disease severity with an individual patient. In many of these cases the seizures are often resistant to both antiepileptic drugs and to immunotherapies. These refractory seizures may lead to the unfavorable long-term cognitive outcomes (46). Indeed, 1 study has shown that within a cohort of patients with temporal lobe epilepsy, the subset with GAD-antibodies often have pharmacoresistant seizures, and their disease is associated with depression and memory dysfunction (Malter et al 2009; 18).

Rasmussen encephalitis has been inconsistently associated with autoantibodies. Despite early suggestions that GluR3 antibodies may be present in these patients, these findings have proven difficult to reproduce (72), and preferential responses to T-cell mediated immunotherapies question a humoral immune-mediated mechanism in the pathogenesis of Rasmussen encephalitis. Whether the T-cell mediated mechanism reflects a viral etiology is yet to be determined.

Table 1. Differences among LGI1, CASPR2, NMDAR-, and GAD-antibody associated forms of encephalitis

	LGI1 and CASPR2	NMDAR	GAD
Male:female	2:1 and 8:1	1:3	1:3
Age	Usually > 50 years old, rarely affecting children	Usually < 40 years old, commonly young children	Wide ranging: 17 to 66 years of age in 1 study (47)
Target antigen	Secreted LGI1 or extracellular domain of CASPR2	Extracellular region of NR1 subunit of NMDAR	GAD-65
Tumor association	Likely reflecting background population in LGI1. If so, SCLC and thymoma. In Morvan syndrome and neuromyotonia, CASPR2-antibodies commonly associate with thymoma.	Ovarian teratoma (in 20%), others rarely	Uncommon
Clinical features	Amnesia, disorientation, temporal lobe seizures, faciobrachial dystonic seizures (with LGI1-only), and affective disturbance. CASPR2 antibodies associate with pain, neuromyotonia, and dysautonomia	Psychiatric features, amnesia, disorientation, and seizures in the first stage of the disease; these progress to a second stage with a movement disorder, dysautonomia, and reduction in consciousness (12; 29)	Temporal lobe seizures, amnesia, and affective disturbance
Distinctive clinical features	Faciobrachial dystonic seizures, which most often precede the amnesia and disorientation (32; 34)	Choreoathetoid movement disorder, mutism, usually starting days to weeks after the psychiatric features	None known but may have co-existing cerebellar ataxia, type 1 diabetes, or stiff person syndrome
Blood tests (other than antibody)	Hyponatremia consistent with SIADH (in around 60%)	None known	None known
MRI	Bilateral hippocampal high signal on T2/FLAIR (in around 60%)	Often normal. Occasionally, non-specific high signal or medial temporal lobe high signal	Bilateral hippocampal high signal on T2/FLAIR
CSF	Most commonly normal	Typically early lymphocytic pleocytosis and later oligoclonal bands	Oligoclonal bands and occasional lymphocytic pleocytosis
Immunotherapy regime	Usually good response to 1 or 2 immunotherapies (steroids +/- IVIG/plasma exchange)	Slow response; often requires > 2 immunotherapies, plus utility of tumor removal	Usually poor touches despite several antiepileptic drugs and immunotherapies

Adapted from (37).

Faciobrachial dystonic seizures. This distinctive seizure semiology was first described in 2008 (32). Most recently this was definitively characterized in 103 patients (63). Faciobrachial dystonic seizures describe a semiology with frequent, brief, highly stereotyped dystonic episodes with arm posturing and ipsilateral face grimacing. These patients have LGI1-antibodies, meaning that the clinical semiology is almost pathognomonic of the underlying molecular diagnosis (36; 63).

The main importance of recognizing faciobrachial dystonic seizures lies in their frequently striking response to immunotherapies and their timing within the natural history of LGI1-antibody-associated encephalitis. Ninety percent of faciobrachial dystonic seizures are antiepileptic drug refractory, with the residual 10% responding to sodium channel blockers over levetiracetam (19). Furthermore, antiepileptic drugs are associated with frequent side effects in these patients, with rashes noted at up to 50% rate. However, faciobrachial dystonic seizures are often very sensitive to immunotherapies, particularly steroids. In addition, intravenous immunoglobulins (IVIG) and plasma exchange have reduced seizure frequency in some patients. Their sensitivity is time-dependent, with greater chances of seizure cessation in those treated earlier, and in those with no cognitive impairment (63).

In around 25% of cases with faciobrachial dystonic seizures, seizure onset is after the cognitive impairment that characterizes LGI1-antibody associated limbic encephalitis. In these cases, the observation of this distinctive semiology should prompt confidence in immunotherapy administration before confirmatory serology is available. More importantly, in around 75% of patients with faciobrachial dystonic seizures, the faciobrachial dystonic seizures preceded the onset of cognitive impairment (63). Therefore, it was hypothesized that treatment of faciobrachial dystonic seizures with immunotherapies may prevent limbic encephalitis (34). Indeed, 2 sequential studies confirmed prevention of cognitive impairment in patients whose faciobrachial dystonic seizures were effectively treated (36; 63). Therefore, the clinical recognition of faciobrachial dystonic seizures may aid an early molecular diagnosis, and it appears to support the prompt administration of corticosteroids, which may prevent otherwise ensuing cognitive impairment (36; 63).

Other autoantibody-mediated epilepsies. In addition, several studies have begun to define other characteristics of autoantibody-mediated seizures, which largely follow the paradigms of faciobrachial dystonic seizures. For example, features that may identify patients with a high likelihood of being immunotherapy-responsive include frequent focal seizures, neuropsychiatric features, brain MRI abnormalities, presence of a neural autoantibody, and an inflammatory CSF (58; Iorio et al 2014; 65). Typically, these features are predictive of LGI1- or CASPR2-autoantibodies (58; 71), but also some cases with other neuronal-surface reactivities (58; 01). Applying these features in a scoring system may in fact help select patents with autoantibody mediated epilepsy from unselected general neurology patients (17).

More specifically, the presence of pilomotor dysfunction, paroxysmal thermal sensations, and bradycardia offer some added specificity towards the diagnosis of an antibody-mediated epilepsy (50; 59; 01). Often these patients have LGI1-antibodies. Although, of course, these semiological features are less specific than faciobrachial dystonic seizures, they remain very helpful in clinical identification of antibody-mediated patients.

Unselected epilepsies associated with antibodies. With greater relevance to the more common epilepsies, it was recognized in 2005 that autoantibodies, particularly against the VGKC-complex, were present in around 10% of patients with antiepileptic drug-refractory and cryptogenic epilepsies (48). Since, it has become apparent that these antibodies rarely represented the likely pathogenic LGI1 or CASPR2 reactivities (“double-negative”). In fact, nearly all fail to bind the extracellular aspects of native neuronal proteins in vitro. Furthermore, several of these double-negative antibodies have been shown to bind the intracellular aspects of VGKCs and to dendrotoxin, a nonmammalian protein used in the VGKC-complex assay (33; 70; 42).

However, double-negative VGKC-complex antibodies appear to be found more commonly in patients with focal epilepsy than in those with generalized epilepsy, and in patients whose seizures respond poorly to antiepileptic drugs (06). Maybe in these and other similar patients they represent a biomarker for an underlying inflammatory process that may be part of the etiology.

In addition, some patients have been reported with seizures and NMDAR-antibodies but few other features characteristically associated with NMDAR-antibodies (51; 30; 39; 25).

In these patients it is unlikely that the antibodies – rarely detected in CSF – are directly pathogenic.

In a large series of patients with new onset refractory status epilepticus (NORSE), it has become recognized that autoantibodies are frequently detected (23). This important study requires more detailed serology to understand whether the VGKC-complex antibodies were double-negatives, or targeted LGI1/CASPR2, and whether the NMDAR-antibodies were also present in CSF.

Postical psychosis and autoantibodies. An intriguing article has proposed that after a seizure, antibodies may access the brain via the breach in blood-brain barrier integrity and generate the well-recognized clinical phenomenon of postictal psychosis. This may account for the typical lucid interval seen between seizure and psychosis and for the self-limiting nature of the condition (57). The role of the blood-brain barrier requires more formal investigations in all the autoimmune encephalopathies. Its role in some rodent models has received preliminary attention (09), but the effects in humans of relative contribution of serum-antibody crossing into CSF, versus the intrathecal production of antibody, needs clarification in order to understand the best compartment to target therapeutically.

CNS autoantibody-mediated syndromes without frequent seizures. By contrast to the above findings, 2 central nervous system autoantibody-related syndromes, Morvan syndrome and neuromyelitis optica, appear to be largely nonepileptogenic. In neuromyelitis optica, the autoimmune process appears to be directed against the aquaporin-4 water channel. The often intense inflammatory infiltrates are seen in neuromyelitis optica pathology, however, the burden of disease affects the spinal cord, optic nerves, and subcortical structures, and this may explain the paucity of seizures. Yet, some patients with antibodies to myelin oligodendrocyte glycoprotein do have encephalitis with prominent seizures and some cortical imaging abnormalities.

In Morvan syndrome, the lack of seizures is far harder to understand. Morvan syndrome has been associated with antibodies often target both CASPR2 and LGI1 either protein alone, and sometimes contactin-2 in addition (35; 44). Given that LGI1-antibodies appear to be epileptogenic in faciobrachial dystonic seizures and limbic encephalitis, and CASPR2-antibodies also associate with some cases of limbic encephalitis, it is difficult to understand why only around 35% of patients with Morvan syndrome develop seizures. Furthermore, these seizures are not especially prominent. It may be that future animal models further help inform this question.

Mesial temporal lobe epilepsy and hippocampal sclerosis as a consequence of autoantibodies. It has been shown that limbic encephalitis was a prodromal illness in around half of adult-onset temporal lobe epilepsy with hippocampal sclerosis. It was suggested that the medial temporal lobe inflammation occurring during limbic encephalitis was the substrate for subsequent atrophy and hippocampal sclerosis (03). This observation may indicate that some cases of adult-onset hippocampal sclerosis can be prevented by prompt recognition and treatment of limbic encephalitis. This possibility is even more intriguing given that cases with faciobrachial dystonic seizures, and perhaps patients with other isolated antibody-mediated epilepsies, may benefit from immunotherapy to prevent the onset of the encephalitis (63). It may be that the natural history of these diseases will alter profoundly with immunotherapies.

Clinical vignette

A 92-year-old hypertensive male presented with a 3-month history of events that synchronously affected his right arm and face. The face was pulled upwards and the arm would supinate and posture upwards. Each event lasted for a few seconds. These began at a frequency of 2 per day and now occurred twice per hour; as a result he was dropping objects in his grasp. Some of the episodes were accompanied by speech arrest and loss of awareness. One month into his illness, his general practitioner commenced carbamazepine. Despite this, attack frequency steadily increased. As he developed a rash, his medication was changed to lamotrigine, again without a reduction in seizure frequency. Neuropsychology assessment and brain MRI were normal. On inspection, the events were identical to cases of faciobrachial dystonic seizures, which have been described above. The patient was treated with 1 g of methylprednisolone and on his third dose the events were much less frequent. After 1 month, no further events were observed. His LGI1-antibodies, sent from the initial clinic visit, were positive (measured using a cell-based assay), and he carried HLA-DRB1*07:01. The steroids were tapered over 6 months with a reduction in LGI1-antibody levels, and there was no return of faciobrachial dystonic seizures.

Biological basis

Etiology and pathogenesis

The antibody-mediated pathogenesis. Accumulating clinical and scientific data suggest that these disorders are caused by antibodies directed against the extracellular surface of neuronal proteins such as the NMDAR and LGI1. After binding to their antigenic target, there are 4 potential mechanisms by which antibodies may affect neuronal function. First, as originally shown with AChR antibodies in myasthenia gravis, the antibodies may cross link surface proteins and internalize the target. This has been confirmed for NMDAR-antibodies (12) and shown to be true for LGI1-antibodies after LGI1 is associated with its natural receptor ADAM22 (63). Second, it is possible that bound antibodies may fix complement and deposit membrane attack complex (MAC) on the target membrane. This has been demonstrated in biopsied or postmortem tissue from patients with LGI1- and CASPR2-antibodies (04), and it is now clear that some LGI1-antibodies are of the IgG1 complement-fixing subclass and that the levels of these IgG1-LGI1 antibodies is proportional to the degree of cognitive impairment in 1 study (63). By contrast, complement deposition was not seen in specimens from patients with NMDAR-antibodies. However, this might be explained by different brain regions examined. Third, antibodies may directly modulate the kinetics or function of the target protein, although this has yet to be convincingly demonstrated in antibody-mediated disorders of the central nervous system. Nevertheless, LGI1-antibodies can bind soluble LGI1 and prevent its interaction with the postsynaptic ADAM22 receptor, consequently reducing AMPA receptor clusters in rat hippocampal neurons (52). In addition, genetic downregulation of LGI1 induced a reduction in presynaptic VGKC currents, and perhaps antibodies to LGI1 will mediate similar effects (61). Finally, it is possible that antibodies could cause direct cytotoxic damage (antibody-mediated cytotoxicity), for example, by modulating calcium or potassium entry to neurons. This mechanism is yet to be proven.

More definitive proof of direct pathogenicity requires behavioral and morphological changes consistent with encephalitis in animals exposed to passive transfer of purified IgG. Indeed, a report has shown that a continuous infusion of NMDAR-antibody into the ventricles of mice causes a behavioral deficit that is consistent with hippocampal, and more widespread cortical, dysfunction. This infusion was associated with specific downregulation of NMDARs and the effect resolved after cessation of antibody infusion (56). Indeed, the pathogenicity of these antibodies is supported by their targeting of neuronal protein extracellular domains, modest correlations between serum levels and clinical features, and genetic or pharmacological paradigms, showing that modulation of these proteins can generate often similar clinical features (70).

The underlying immunology. By contrast to the effector mechanisms of autoantibodies, the immunobiology underlying these conditions has received relatively little attention. This knowledge seems key to understand etiology and disease perpetuation. One study has shown that lymphocytes derived from the circulation of patients have the capacity to produce NMDAR-directed autoantibodies (45). These B cells can be stimulated under defined conditions to differentiate into antibody-secreting cells, and produce NR1-autoantibody specificities at levels that correlate with the serum NR1-autoantibody levels. In addition, low to moderate levels of NR1-directed IgM autoantibodies can be observed in patient sera at a variety of time points from disease onset. These novel observations suggest that germinal center reactions may account for a significant proportion of NR1-autoantibody production in vivo. The main germinal centers are likely to be within lymph nodes. In addition, the ovarian teratoma contains T-B cell lymphoid aggregates and the intratumoral lymphocytes can secrete the NR1-autoantibodies. Hence, the teratoma may also be considered a germinal center.

Although small reports suggest NMDAR-antibody encephalitis shows no HLA bias, observations from patients with LGI1 antibodies show a striking MHC class 2 association. Around 90% of 40 patients from differing ethnic backgrounds showed an association with HLA-DRB1*07:01 (40; 68). We have also extended this association to 68 further UK and U.S. patients and demonstrated linkage with several other class 2 and two class 1 loci (70; 05). These observations strongly implicate T cell initiated pathology in patients with LGI1-antibodies and mean that T cell modulating therapies may have important implications for future immunotherapy strategies.

Management

The autoantibody studies showing treatment effects and outcomes in epilepsy have been summarized by Bakpa and colleagues (02).

The mainstays of management are symptomatic therapies (eg, antiepileptic drugs and drugs to control dyskinesias), observation for complications characteristically associated with the antibody (eg, NMDAR-antibodies and dysautonomia), reduction of antibody levels with immunotherapies, and tumor removal where relevant.

The tumor removal may act to eliminate lymphocytes within an active germinal center and a source of antigen that stimulates the ongoing immune reactions (45). Although mechanisms of action of corticosteroids and IVIG have been reviewed in great detail, the effect of plasma exchange – removal of circulating antibodies – in CNS conditions has only recently been studied. One elegant study has suggested that the effect may relate to a concomitant reduction in serum autoantibodies, which may correlate with clinical efficacy (15). This intriguing possibility requires further prospective studies to understand the relative timings of antibody reduction and clinical outcomes.

The available data are broadly consistent among studies. First, it is clear that steroids are of benefit in LGI1-antibody encephalitis for seizure control and for reduction of cognitive deficits (30; 36). Although steroids alone may be sufficient for some patients with LGI1-antibodies, IVIG or plasma exchange are reasonable alternatives, and few patients appear refractory to steroids plus 1 of these other 2 options (62). However, long-term outcomes have not been associated with the type of treatment interventions (08).

By contrast, around 50% of patients with NMDAR-antibody encephalitis make a good response to combinations of steroids, IVIG, and plasma exchange. The remaining 50% of patients show an improved outcome with additional therapies, such as cyclophosphamide or rituximab (13; 64). A study suggested a poor long-term cognitive outcome in NMDAR-antibody encephalitis treated with late or limited immunotherapies (20).

Patients with GAD-antibody associated limbic encephalitis tend to have a poor outcome despite often-aggressive immunotherapy (47; 21). Novel therapeutic options are required in this group and may include drugs such as rituximab (43) and bortezomib (60), which eliminate nonplasma cell B cells and plasma cells, respectively.

References

01: Aurangzeb S, Symmonds M, Knight RK, Kennett R, Wehner T, Irani SR. LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures. Seizure 2017;50:14-7. PMID 28586706
02: Bakpa OD, Reuber M, Irani SR. Antibody-associated epilepsies: clinical features, evidence for immunotherapies and future research questions. Seizure 2016;41:26-41. PMID 27450643
03: Bien CG, Urbach H, Schramm J, et al. Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy. Neurology 2007;69(1 2):1236-44.** PMID 17875912
04: Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012;135(5):1622-38. PMID 22539258
05: Binks SNM, Klein CJ, Waters P, Pittock SJ, Irani SR. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. J Neuro Neurosurg Psychiatry 2018;89(5):526-34.** PMID 29055902
06: Brenner T, Sills GJ, Hart Y, et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia 2013;54(6):1028-35. PMID 23464826
07: Brierley JB, Corsellis JAN, Hierons R, Nevin S. Subacute encephalitis of later adult life mainly affecting the limbic areas. Brain 1960;83(3):357-68.
08: Butler CR, Miller TD, Kaur MS, et al. Persistent anterograde amnesia following limbic encephalitis associated with antibodies to the voltage-gated potassium channel complex. J Neurol Neurosurg Psychiatry 2014;85(4):387-91. PMID 24403282
09: Castillo-Gomez E, Kästner A, Steiner J, et al. The brain as immunoprecipitator of serum autoantibodies against N-Methyl-D-aspartate receptor subunit NR1. Ann Neurol 2016;79(1):144-51. PMID 26505629
10: Corsellis JA, Goldberg GJ, Norton AR. Limbic encephalitis and its association with carcinoma. Brain 1968;91(3):481-96. PMID 5723018
11: Dale RC, Irani SR, Brilot F, et al. N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol 2009;66(5):704-9.** PMID 19938173
12: Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7(12):1091-8. PMID 18851928
13: Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10(1):63-74.** PMID 21163445
14: Dogan Onugoren M, Deuretzbacher D, Haensch CA, et al. Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neuro Neurosurg Psychiatry 2015;86(9):965-72. PMID 25300449
15: Dogan Onugoren M, Golombeck KS, Bien C, et al. Immunoadsorption therapy in autoimmune encephalitides. Neurol Neuroimmunol Neuroinflamm 2016;3(2):e207.** PMID 26977423
16: Doss S, Wandinger KP, Hyman BT, et al. High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. Ann Clin Transl Neurol 2014;1(10):822-32. PMID 25493273
17: Dubey D, Alqallaf A, Hays R, et al. Neurological autoantibody prevalence in epilepsy of unknown etiology. JAMA Neurol 2017;74(4):397-402. PMID 28166327
18: Falip M, Carreño M, Miró J, et al. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol 2012;19(6):827-33. PMID 22353320
19: Feyissa AM, López Chiriboga AS, Britton JW. Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm 2017;4(4):e353. PMID 28680914
20: Finke C, Kopp UA, Pruss H, Dalmau J, Wandinger KP, Ploner CJ. Cognitive deficits following anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry 2012;83(2):195-8. PMID 21933952
21: Frisch C, Malter MP, Elger CE, Helmstaedter C. Neuropsychological course of voltage-gated potassium channel and glutamic acid decarboxylase antibody related limbic encephalitis. Eur J Neurol 2013;20(9):1297-304. PMID 23678940
22: Gadoth A, Pittock SJ, Dubey D, et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG positive patients. Ann Neurol 2017;82(1):79-92. PMID 28628235
23: Gaspard N, Foreman BP, Alvarez V, et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology 2015;85(18):1604-13.** PMID 26296517
24: Geschwind MD, Tan KM, Lennon VA, et al. Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob disease. Arch Neurol 2008;65(10):1341-6. PMID 18852349
25: Goldberg EM, Taub KS, Kessler SK, Abend NS. Anti-NMDA receptor encephalitis presenting with focal non-convulsive status epilepticus in a child. Neuropediatrics 2011;42(5):188-90. PMID 22109736
26: Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75(8):1135-40.** PMID 15258215
27: Iorio R, Assenza G, Tombini M, et al. The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy. Eur J Neurol 2015;22(1):70-8. PMID 25112548
28: Irani SR. ‘Moonlighting’ surface antigens: a paradigm for autoantibody pathogenicity in neurology? Brain 2016;139(Pt 2):304-6. PMID 26912515
29: Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010b;133(9):2734-48.** PMID 20663977
30: Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010a;133(6):1655-67. PMID 20511282
31: Irani SR, Bien CG, Lang B. Autoimmune epilepsies. Curr Opin Neurol 2011a;24(2):146-53. PMID 21358545
32: Irani SR, Buckley C, Vincent A, et al. Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology 2008;71(20):1647-8. PMID 18815385
33: Irani SR, Gelfand JM, Al-Diwani A, Vincent A. Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol 2014;76(2):168-84. PMID 24930434
34: Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011b;69(5):892-900. PMID 21416487
35: Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012;72(2):241-55. PMID 22473710
36: Irani SR, Stagg CJ, Schott JM, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013;136(Pt 10):3151-62.** PMID 24014519
37: Irani SR, Vincent A. NMDA Receptor antibody encephalitis. Curr Neurol Neurosci Rep 2011;11(3):298-304. PMID 21331529
38: Jagota P, Vincent A, Bhidayasiri R. Transplacental transfer of NMDA receptor antibodies in an infant with cortical dysplasia. Neurology 2014;82(18):1662-3. PMID 24706012
39: Johnson N, Henry C, Fessler AJ, Dalmau J. Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology 2010;75(16):1480. PMID 20826712
40: Kim TJ, Lee ST, Moon J, et al. Anti-LGI1 encephalitis is associated with unique HLA subtypes. Ann Neurol 2017;81(2):183-92. PMID 28026029
41: Kumar MA, Jain A, Dechant VE, et al. Anti-N-methyl-D-aspartate receptor encephalitis during pregnancy. Arch Neurol 2010;67(7):884-7. PMID 20625099
42: Lang B, Makuch M, Moloney T, et al. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. J Neurol Neurosurg Psychiatry 2017;88(4):353-61.** PMID 28115470
43: Lee WJ, Lee ST, Byun JI, et al. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology 2016;86(18):1683-91.** PMID 27037228
44: Loukaides P, Schiza N, Pettingill P, et al. Morvan's syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complex. J Neurol Sci 2012;15:52-6. PMID 21906755
45: Makuch M, Wilson R, Al-Diwani A, et al. N-methyl-D-aspartate receptor antibody production from germinal center reactions: therapeutic implications. Ann Neurol 2018;83(3):553-61.** PMID 29406578
46: Malter MP, Frisch C, Zeitler H, et al. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure 2015;30:57-63. PMID 26216686
47: Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010;67(4):470-8.** PMID 20437582
48: McKnight K, Jiang Y, Hart Y, et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 2005;65(11):1730-6. PMID 16344514
49: Mohammad SS, Jones H, Hong M, et al. Symptomatic treatment of children with anti-NMDAR encephalitis. Dev Med Child Neurol 2015;58(4):376-84. PMID 26330176
50: Naasan G, Irani SR, Bettcher BM, Geschwind MD, Gelfand JM. Episodic bradycardia as neurocardiac prodrome to voltage-gated potassium channel complex/leucine-rich, glioma inactivated 1 antibody encephalitis. JAMA Neurol 2014;71(10):1300-4. PMID 25133690
51: Niehusmann P, Dalmau J, Rudlowski C, et al. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol 2009;66(4):458-64. PMID 19364930
52: Ohkawa T, Fukata Y, Yamasaki M, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013;33(46):18161-74. PMID 24227725
53: Palace J, Lang B. Epilepsy: an autoimmune disease. J Neurol Neurosurg Psychiatry 2000;69(6):711-4. PMID 11080217
54: Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014;13(3):276-86. PMID 24462240
55: Pettingill P, Kramer HB, Coebergh JA, et al. Antibodies to GABAA receptor alpha1 and gamma2 subunits: clinical and serologic characterization. Neurology 2015;84(12):1233-41. PMID 25636713
56: Planaguma J, Leypoldt F, Mannara F, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 2015;138(Pt 1):94-109. PMID 25392198
57: Pollak TA, Nicholson TR, Mellers JD, Vincent A, David AS. Epilepsy-related psychosis: A role for autoimmunity. Epilepsy Behav 2014;16:33-8. PMID 24840753
58: Quek AM, Britton JW, McKeon A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012;69(5):582-93. PMID 22451162
59: Rocamora R, Becerra JL, Fossas P, et al. Pilomotor seizures: an autonomic semiology of limbic encephalitis? Seizure 2014;23(8):670-3. PMID 24890932
60: Rüegg S, Irani SR. The trouble with plasma cells: getting to the root cause. Neurology 2017;88(4):340-1. PMID 28003504
61: Seagar M, Russier M, Caillard O, et al. LGI1 tunes intrinsic excitability by regulating the density of axonal Kv1 channels. Proc Natl Acad Sci USA 2017;114(29):7719-24.** PMID 28673977
62: Shin YW, Lee ST, Shin JW, et al. VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J. Neuroimmunol 2013;265(1-2):75-81.
63: Thompson J, Bi M, Murchison AG, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 2018;141(2):348-56.** PMID 29272336
64: Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12(2):157-65.** PMID 23290630
65: Toledano M, Britton JW, McKeon A, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 2014;82(18):1578-86. PMID 24706013
66: Tuzun E, Erdag E, Durmus H, et al. Autoantibodies to neuronal surface antigens in thyroid antibody-positive and -negative limbic encephalitis. Neurol India 2011;59(1):47-50. PMID 21339658
67: van Sonderen A, Ariño H, Petit-Pedrol M, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology 2016a;87(5):521-8. PMID 27371488
68: van Sonderen A, Roelen DL, Stoop JA, et al. Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4. Ann Neurol 2017;81(2):193-8. PMID 28026046
69: van Sonderen A, Schreurs MW, de Bruijn MA, et al. The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies. Neurology 2016b;86(18):1692-9.** PMID 27037230
70: Varley J, Vincent A, Irani SR. Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions. J Neurol 2015;262(4):1081-95. PMID 25491076
71: von Podewils F, Suesse M, Geithner J, et al. Prevalence and outcome of late-onset seizures due to autoimmune etiology: a prospective observational population-based cohort study. Epilepsia 2017;58(9):1542-50. PMID 28681401
72: Watson R, Jiang Y, Bermudez I, et al. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology 2004;63(1):43-50. PMID 15249609
73: Wright S, Hashemi K, Stasiak L, et al. Epileptogenic effects of NMDAR antibodies in a passive transfer mouse model. Brain 2015;138(Pt 11):3159-67. PMID 26373601

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Sarosh R Irani MD

Dr. Irani of the University of Oxford received royalties from Nil as a patent joint applicant.
See Profile

Editor

Jerome Engel Jr MD PhD

Dr. Engel of the David Geffen School of Medicine at the University of California, Los Angeles, has no relevant financial relationships to disclose.
See Profile

Former Authors

Bethan Lang PhD and Angela Vincent MBBS

Patient Profile

Age range of presentation: 0-01 month

01-23 months

02-05 years

06-12 years

13-18 years

19-44 years

45-64 years

65+ years
Sex preponderance: Differs for each antibody; see Table 1.
Heredity: Heredity may be a factor: unclear but probable that there is a polygenic component to susceptibility including the established HLA association for LGI1-antibodies.
Population groups selectively affected: The non-Caucasian often Afro-Caribbean, Oriental, and Pacific Island populations are at increased risk of NMDAR-antibody encephalitis (Mohammad et al 2015). By contrast, patients with LGI1-antibodies are only very rarely of AfroCaribbean extraction (Thompson et al 2018).
Occupation groups selectively affected: None known to be selectively affected

ICD & OMIM codes

ICD-9: Other causes of encephalitis and encephalomyelitis: 323.81
ICD-10: Encephalitis, myelitis, and encephalomyelitis, unspecified: G04.9

Encephalitis, myelitis, and encephalomyelitis in other diseases: G05.8

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Antibody-mediated epilepsies

Associated Disorders

Paraneoplastic encephalitis
Paraneoplastic limbic encephalitis
Epilepsy
Rapidly progressive dementia

Differential Diagnosis

Wernicke-Korsakoff syndrome
Infective encephalitis, especially HSV
Drug/toxin overdose, eg, ketamine
Encephalitis lethargica
Creutzfeldt-Jacob disease
- Dementia
- Hashimoto encephalopathy

Also Relevant

Autoantibodies
Epilepsy
Immunotherapy in neuromuscular disorders
Movement disorders associated with autoimmune encephalitis
Paraneoplastic limbic encephalitis

Antibody-mediated epilepsies …

Antibody-mediated epilepsies

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Differences among LGI1, CASPR2, NMDAR-, and GAD-antibody associated forms of encephalitis

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Photosensitive occipital lobe epilepsy

Intermittent explosive disorder

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Reflex seizures

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

Antibody-mediated epilepsies

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Differences among LGI1, CASPR2, NMDAR-, and GAD-antibody associated forms of encephalitis

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Photosensitive occipital lobe epilepsy

Intermittent explosive disorder

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Reflex seizures

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

This is an article preview.
Start a Free Account
to access the full version.